Trials / Completed
CompletedNCT02865005
Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Comparing Dapsone 5% Gel (SEEGPharm SA) to Aczone® and Both Active Treatments Compared to Placebo (Vehicle) in the Treatment of Acne Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,361 (actual)
- Sponsor
- Seegpharm S.A. · Industry
- Sex
- All
- Age
- 12 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris.
Detailed description
Multi-center, double-blind, randomized, placebo-controlled trial of Dapsone 5.0% Gel in the treatment of acne vulgaris for 84 days in male and female subjects age 12-40.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapsone 5.0% Gel (SEEGPharm) | Topical Gel |
| OTHER | Placebo | Topical Gel |
| DRUG | Dapsone 5.0% Gel (Allergan) | Topical Gel |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2016-11-01
- Completion
- 2016-12-01
- First posted
- 2016-08-12
- Last updated
- 2016-12-20
Locations
36 sites across 2 countries: United States, Belize
Source: ClinicalTrials.gov record NCT02865005. Inclusion in this directory is not an endorsement.